Tavneos® newly introduced in the 2022 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV) Recommendations recognize Tavneos®’ ability to induce and sustain remission, lower glucocorticoids-induced toxic effects…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.